The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
EMA grants PRIME designation to anti-CD30 CAR-T cell therapy for the treatment of patients with R/R cHL
On January 18, 2021, it was announced that the European Medicines Agency (EMA) granted Priority Medicines (PRIME) designation to CD30-targeting chimeric antigen receptor (CAR)-T cells, TT11 CD30.CAR-T cells, for the treatment of relapsed/refractory (R/R) classical Hodgkin lymphoma (cHL).1
The decision was based on results of two parallel phase I/II trials (NCT02690545 and NCT02917083) investigating the efficacy and safety of TT11 CD30.CAR-T cells, which were published in the Journal of Clinical Oncology. These results were previously reported on the Lymphoma Hub and showed that ~60% of patients treated at the highest dose level had a complete disappearance of tumor, with no serious toxicities.1
TT11 CD30.CAR-T cell therapy2
- Targets CD30, a member of the tumor necrosis factor receptor superfamily, that is expressed on cancerous cells in Hodgkin lymphoma and various non-Hodgkin lymphomas, but only in a small subset of activated T and B cells, which reduces the likelihood of off-target-related adverse effects.
- Has demonstrated encouraging efficacy results and a favorable toxicity profile in heavily pretreated patients with Hodgkin lymphoma.
- Previously granted Regenerative Medicine Advanced Therapy designation from the U.S. Food and Drug Administration (FDA).
- Also being investigated in a phase I trial (NCT04526834) for patients with R/R CD30-positive non-Hodgkin lymphoma.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content